Update on Ulcerative Colitis Program Separately
Post# of 72447
(Total Views: 336)
Posted On: 12/10/2019 9:46:34 AM
Update on Ulcerative Colitis Program
Separately, management would like to provide a brief update on the planned independently-sponsored clinical study of Brilacidin for Ulcerative Colitis, a common type of IBD. Last month, Brilacidin was shipped from the drug manufacturer to the Company’s partner, BDD Pharma, for human testing using the delayed-release tablet formulation. Furthermore, the required regulatory paperwork has been submitted to the health authorities for the upcoming study. The Company plans to provide future updates on this trial as appropriate
Separately, management would like to provide a brief update on the planned independently-sponsored clinical study of Brilacidin for Ulcerative Colitis, a common type of IBD. Last month, Brilacidin was shipped from the drug manufacturer to the Company’s partner, BDD Pharma, for human testing using the delayed-release tablet formulation. Furthermore, the required regulatory paperwork has been submitted to the health authorities for the upcoming study. The Company plans to provide future updates on this trial as appropriate
(1)
(0)